Ceritinib (LDK378)
| Price | $1 |
| Package | 1KG |
| Min. Order: | 1KG |
| Supply Ability: | 100kg |
| Update Time: | 2019-07-06 |
Product Details
| Product Name: Ceritinib (LDK378) | CAS No.: 1032900-25-6 |
| Min. Order: 1KG | Purity: 99% |
| Supply Ability: 100kg | Release date: 2019/07/06 |
JD607
| Product Name: | Ceritinib (LDK378) |
| Synonyms: | LDK378;5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine;5-chloro-N2-(2-isopropoxy-5-Methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyriMidine-2,4-diaMine;LDK378/LDK-378;5-Chloro-N4-[2-[(1-Methylethyl)sulfonyl]phenyl]-N2-[5-Methyl-2-(1-Methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyriMidinediaMine;ceritinib;LDK378 Ceritinib;Ceritinib (LDK378) |
| CAS: | 1032900-25-6 |
| MF: | C28H36ClN5O3S |
| MW: | 558.13514 |
| EINECS: | -0 |
| Product Categories: | API;Inhibitors |
| Mol File: | 1032900-25-6.mol |
 |
|
| Ceritinib (LDK378) Chemical Properties |
| Safety Information |
| MSDS Information |
| Ceritinib (LDK378) Usage And Synthesis |
| Indications and Usage | Ceritinib is a new ALK gene inhibitor (ALKi) developed by Novartis Pharmaceuticals; its commercial name is Zykadia, and its previous code was LDK378. It was approved by the FDA for sale on April 29, 2014, and it is used to treat anaplastic lymphoma kinase (ALK) positive transfer of crizotinib (CRZ) progress or intolerance of non-small cell lung cancer (NSCLC). |
| Mechanisms of Action | Crizotinib resistance is a major issue for patients undergoing treatment for ALK gene rearrangement positive non-small cell lung cancer. Ceritinib is a kind of ALK tyrosine kinase inhibitor. Ceritinib does not target the MET proto-oncogene, but instead inhibits the insulin-like growth factor 1 receptor and blocks proteins from promoting cancer cell development, thus inhibiting the expression of EML4-ALK and NPM-ALK fusion protein cells. It is used to treat ALK rearrangement positive NSCLC patients who have previously used Crizotinib and can overcome Crizotinib resistance. Compared to Crizotinib, Ceritinib does not inhibit MET kinase activity, but inhibits IGF-1 receptors. Whether in terms of enzyme reaction, cell analysis or Crizotinib resistant animal models, research results all show that Ceritinib is more effective than Crizotinib. Additionally, regardless of any ALK resistance mutation, Ceritinib is still highly effective. In clinical models, Ceritinib’s ALK inhibition has 20 times the tumor-fighting effect of Crizotinib. Ceritinib also has the same effect on Crizotinib resistant central nervous system lesion NSCLC. Clinical trials show that Ceritinib can effectively inhibit ALK targets, potentially affecting an unknown kinase related to drug resistance, thus overcoming Crizotinib resistance. |
| Patents | American patent numbers: US7153964，US7893074，US7964592，US8039474，US8039479，US8377921，US8703787. Patent expiration dates: February 26, 2021 (US7153964) April 25, 2026 (US7893074) January 13, 2027 (US7964592) June 29, 2030 (US8039474, US8039479) November 20, 2027 (US8377921) April 29, 2032 (US8703787) Patents belong to Novartis |
| Definition | ChEBI: A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer. |
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates：
Pharmaceutical intermediates;
OLED intermediates;
You may like
-
![6-Hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one](https://img.chemicalbook.com/ProductImageEN/2018-8/Large/c51f4c59-96fa-40dd-a252-3b57ac0444c0.gif)
CAS:868049-49-4
$1.00 / 1KG
-
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-12-12 | |
| $45.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-18 | |
| $0.00/1kg |
VIP1Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-05-07 | |
| $0.00/1kg |
Nanjing Fred Technology Co., Ltd
|
2023-12-14 | ||
| $0.00/1kg |
XuZhou Magic Biotechnology Co., Ltd.
|
2023-08-03 | ||
| $0.00/1kg |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-30 | |
| $9.00/1g |
Hebei Linwo New Material Technology Co., LTD
|
2022-07-05 | ||
| $1.00/1kg |
Wuhan Dujiang Industrial Co., Ltd.
|
2022-03-09 | ||
| $0.00/25Kg/Bag |
Shenzhen Shengda Pharma Limited
|
2022-03-04 |
China- Since: 2014-12-17
- Address: No.967,15th Floor,Unit 7, Building 1, No.70 of DianChang Road, High-tech Development Zone, Zhengzho
INQUIRY
楊俊青
sales@coreychem.com
sales@coreychem.com